Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 92

Medical Radiopharmaceuticals Pharmaceutical Radiation 92

Imaging Technology

JANUARY 12, 2024

Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Medicare Clinic 105

Imaging Technology

NOVEMBER 26, 2023

milla1cf Sun, 11/26/2023 - 09:00 November 26, 2023 — TeleDaaS, PLLC , a leading dosimetry-as-a-service provider, made its official debut today at the Radiological Society of North America’s annual meeting, # RSNA2023. This is already showing promise with several ongoing trials of approved and developmental radiopharmaceuticals.

Clinic 78

Clinic Radiopharmaceuticals Radiosensitivity Pharmaceutical 78

Imaging Technology

AUGUST 29, 2023

Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue. It supports a sustainable future for radiopharmaceuticals unencumbered by manufacturing, logistical and environmental issues inherent to many radiopharmaceuticals.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

Imaging Technology

AUGUST 23, 2023

milla1cf Wed, 08/23/2023 - 19:19 August 23, 2023 — RefleXion Medical , a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX biology-guided radiotherapy on the RefleXion X1 machine at the Stanford Medicine Cancer Center.

Radiopharmaceuticals 98

Radiopharmaceuticals Disease Radiation Clinic 98

Imaging Technology

OCTOBER 18, 2023

About Targeted Alpha Therapy Targeted Alpha Therapy is an emerging class of cancer therapeutics, which seeks to deliver alpha radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g.,

Radiopharmaceuticals 115

Radiopharmaceuticals Pharmaceutical Radiation Medical 115

AuntMinnie

OCTOBER 2, 2024

Horowitz, et al, Medical Hypotheses , October 13, 2023. Plesner, et al, Radiology , September 26, 2023. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. Kochanova, et al, Scientific Reports , September 19, 2023. Huang, et al, JAMA Network Open , October 5, 2023.

Digital Imaging and Communications in Medicine 137

Digital Imaging and Communications in Medicine X-ray MRI Hospital 137

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

SEPTEMBER 27, 2023

from October 1 to 4, 2023. from October 1 to 4, 2023. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga., Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga., Gauden , D.Phil.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

AuntMinnie

JULY 18, 2024

Standardized guidelines can help radiologists navigate the legal landscape of imaging pregnant women with ionizing radiation, according to a July 15 editorial published in the Journal of the American College of Radiology ( ACR ). The ACR and SPR in 2023 updated their practice parameter for this area of imaging.

Radiologist 78

Radiologist Imaging Radiography Fluoroscopy 78

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

TTG Imaging Solutions

AUGUST 10, 2023

Pete has over 20 years in the nuclear pharmacy industry and over 15 years in nuclear pharmacy management including expertise in logistics, complex supply chain management and radiopharmaceutical drug chemistry and formulation. Pete assumed the role of Vice President of Pharmacy Operations in 2023.

Radiopharmaceuticals 40

Radiopharmaceuticals Radiation Imaging 40

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 88

Nuclear Medicine Radiation Oncology Nursing Radiation 88

Imaging Technology

JULY 28, 2023

Food and Drug Administration (FDA) on May 25, 2023. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure. POSLUMA was approved by the U.S. manufacturer and distributor.

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., The acquisition closed on May 4, 2023.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. manufacturer and distributor, PETNET Solutions Inc, A Siemens Healthineers Company.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

OCTOBER 5, 2023

We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.”

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

JULY 25, 2023

milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

Imaging Technology

JULY 11, 2023

milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 Gauden , D.Phil.,

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

AUGUST 30, 2023

milla1cf Wed, 08/30/2023 - 14:45 August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children’s Hospital Medical Center shows that multiple beams and intervals in delivery during FLASH proton therapy treatment reduced skin-saving effects in preclinical models.

Radiation Oncology 111

Radiation Oncology Radiation Radiopharmaceuticals Clinic 111